Overview of Acton Prolongatum

Quick Facts

Property	Description
Active Ingredient	Corticotrophin (ACTH)
Form	Injectable Suspension (Depot)
Pharmacological Class	Pituitary Hormone
General Purpose	Stimulates Adrenal Hormone Production
Origin	Biological Origin (Natural Peptide)

Acton Prolongatum is a prescription-only medicine whose active ingredient is Corticotrophin, officially known as Adrenocorticotropic Hormone (ACTH). It is categorized as an adrenocorticotropic hormone and belongs to the broader pituitary hormone therapeutic class. This medication is notably of biological origin, utilizing a highly purified natural peptide, distinguishing it from fully synthetic analogues.

Composition and Unique Depot Formulation

The medicine is supplied as a single-component injectable suspension, specifically designated as a Repository Corticotropin Injection. The active Corticotrophin is suspended in an oil-based vehicle or equivalent sustained-release medium, which separates it from standard aqueous injections. This formulation is designed to provide a sustained physiological effect. The name 'Prolongatum' refers directly to this engineering, ensuring the hormone is absorbed slowly from the intramuscular (IM) injection site, minimizing fluctuations in hormone levels.

General Purpose: Stimulating the Body's Own Hormones

The primary function of Acton Prolongatum is to act as a signaling agent that targets the adrenal cortex. It is not a replacement steroid; rather, Corticotrophin stimulates the adrenal glands to increase the synthesis and release of their own natural hormones, particularly glucocorticoids. This provides an indirect but powerful hormonal influence to modulate the body's immunoregulatory and anti-inflammatory systems, which is the general therapeutic goal of its use. This fundamental action is characterized by the efficacy of ACTH in stimulating adrenal output.

Regulatory References

NIH StatPearls on Adrenocorticotropic Hormone (ACTH)

What side effects are possible with Acton Prolongatum?

Adverse Reactions by System and Frequency

The official safety profile for Acton Prolongatum (Repository Corticotropin Injection) details adverse effects across multiple body systems, reflecting its function in stimulating endogenous hormone production. The documented adverse reactions are categorized by frequency based on regulatory data.

System-Organ Class	Very Common (ge 10%)	Common (1% to 10%)
Infections	Infections (Increased risk)	—
Cardiovascular	Hypertension (High blood pressure)	Cardiac Hypertrophy (Infants/Children)
Nervous System	Convulsions (Seizures)	—
Endocrine/Metabolic	—	Cushingoid appearance, Fluid retention, Weight gain
General	Irritability, Pyrexia (Fever)	—

Serious Adverse Reactions

Specific serious risks are highlighted in regulatory documents:

Hormonal Instability: Risk of Cushing's Syndrome from prolonged therapy and Adrenal Insufficiency if the medicine is suddenly stopped after extended use.
Gastrointestinal Risk: Potential for Gastrointestinal Perforation and Bleeding due to peptic ulcer risk, with symptoms possibly being masked.
Allergic Reactions: Risk of Severe Allergic Reactions (Anaphylaxis) due to the medicine's porcine-derived protein origin.

Population and Duration-Specific Safety Notes

Safety constraints are documented for specific contexts:

Prolonged Use: Associated with a decrease in bone density (Osteoporosis) and the development of Cataracts or Glaucoma. Withdrawal after prolonged use must be managed carefully to avoid Adrenal Insufficiency.
Pediatric Safety: Prolonged use in children may negatively impact skeletal growth and physical development.
Comorbid Conditions: The therapy may worsen symptoms of pre-existing conditions such as diabetes or myasthenia gravis, and may mask signs of underlying infection. Use with live vaccines is generally restricted during immunosuppressive dosing.

Overdose and Emergency Response

The official regulatory documents for Repository Corticotropin Injection (Acton Prolongatum) define the overdose profile primarily through the consequences of chronic overexposure and prolonged high dosage, rather than acute single-dose toxicity. Manifestations are linked to excessive stimulation of the adrenal cortex, resulting in clinical signs consistent with Cushing's Syndrome, including hypertension and salt and water retention. These effects can also lead to hypokalemia and documented mood disturbances.

Due to the drug's effect on the HPA axis, a severe, life-threatening outcome associated with overexposure is the risk of Adrenal Insufficiency upon medication withdrawal. Regulatory labeling mandates that the dose must be gradually tapered when discontinuing therapy. Immediate medical attention must be sought for suspected severe complications of overexposure, such as the onset of Adrenal Insufficiency symptoms or the development of complications like Gastrointestinal perforation or bleeding. Supportive management measures described in regulatory texts include dietary salt restriction and potassium supplementation to manage fluid and electrolyte disturbances. Special regulatory note is given to pediatric patients on long-term therapy, who must be monitored for adverse effects on growth and physical development.

Therapeutic Uses of Acton Prolongatum

What Acton Prolongatum Treats: Main Uses and Benefits

Acton Prolongatum (Corticotrophin Injection) is commonly used to help manage symptoms related to severe inflammatory and autoimmune conditions. It is applied across domains where additional symptomatic support is needed for heightened physiological activity.

Core Therapeutic Applications

The medication is applied in situations involving certain distressing symptoms, including the management of infantile spasms (West syndrome) and acute exacerbations (relapses) of multiple sclerosis in adults. It is also applied in autoimmune and collagen diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), certain severe dermatological conditions, and specific nephrotic syndromes to assist with symptom management.

“The medication offers supportive therapeutic benefit when symptoms become temporarily overwhelming, assisting patients with coping more steadily with difficult episodes.”

In these scenarios, the medication contributes to easing the overall symptom load during acute phases, which may involve pronounced joint pain, swelling, neurological deficits, or fluid imbalances. This application is relevant in situations where symptoms create noticeable physiological strain or interfere with daily functioning.

Quick Fact: Relief for Acute Inflammation

Domain	Symptom Cluster Addressed	Therapeutic Support Focus
Neurology	Severe episodic spasms, acute neurological deficits	Assists with maintaining functional stability during acute phases
Rheumatology	Pronounced systemic inflammation, joint swelling	Contributes to easing the overall symptom load
Nephrology	Proteinuria and related edema	Relevant for easing symptomatic fluid imbalance

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility and Contraindications

Official regulatory information strictly defines the population eligible to use Corticotrophin Repository Injection (Acton Prolongatum). Use is established in adults for conditions like acute exacerbations of multiple sclerosis and in infants and children under 2 years of age for infantile spasms. However, pediatric patients on long-term therapy require close monitoring for effects on growth and development.

Absolute Contraindications

The medicine is contraindicated (must not be used) in patients with specific conditions, including:

Cardiovascular and Gastrointestinal Comorbidities: Congestive heart failure, uncontrolled hypertension, history of or the presence of a peptic ulcer, and recent surgery.
Infections and Immunological Status: Systemic fungal infections, ocular herpes simplex, and those receiving live or live attenuated vaccines.
Skeletal and Autoimmune Conditions: Scleroderma and osteoporosis.
Endocrine and Hypersensitivity: Primary adrenocortical insufficiency, adrenocortical hyperfunction, or known sensitivity to porcine proteins (due to the drug's origin).

Conditional or Restricted Use

Pregnancy and Lactation: Use is generally not recommended during pregnancy due to documented risks, and caution is advised during breastfeeding due to insufficient data on infant risk.

Organ and Metabolic Status: The medicine requires caution in patients with liver cirrhosis, hypothyroidism, renal insufficiency, or diabetes, as its effects may be enhanced or require specialized management.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Acton Prolongatum (Corticotrophin) is defined by pharmacodynamic effects and specific procedural constraints, with no formal documentation of interactions involving CYP enzymes or major drug transporters. The regulatory labeling does not explicitly list interactions with food, alcohol, or herbal products.

Classification	Official Regulatory Documentation
Interaction Severity Classification	Contraindicated (Vaccines); Caution (Diuretics, Aspirin/Hypoprothrombinemia)
Regulatory Basis	FDA Labeling (Prescribing Information)
Interaction-Context Constraints	Interaction with vaccines is constrained to immunosuppressive doses.

Official Interaction Statements:

Live or Live Attenuated Vaccines are contraindicated when corticotrophin is administered at immunosuppressive doses, a restriction documented due to the risk of neurological complications and impaired antibody response.
Concomitant use with diuretics may accentuate electrolyte loss, a pharmacodynamic effect arising from the medicine's influence on endogenous steroid production.
Aspirin should be used cautiously in conjunction with corticotrophin in patients with the pre-existing condition of hypoprothrombinemia.

The official regulatory documents structure the product's interaction information around these specific constraints, highlighting combinations that require prohibition or heightened caution based on the potential for additive effects or procedural risks.

Mechanism of Action

Acton Prolongatum, containing corticotropin, functions as a long-acting Adrenocorticotropic Hormone (ACTH) analogue. Following intramuscular or subcutaneous injection, its active component selectively targets the adrenal cortex.

It interacts as an agonist at melanocortin 2 receptors (MC2R), which are G-protein-coupled receptors. This binding initiates the activation of adenylyl cyclase, which catalyzes the conversion of ATP to cyclic adenosine monophosphate (cAMP), the intracellular second messenger.

The increase in intracellular cAMP levels activates protein kinase A (PKA). PKA then initiates a cascade that promotes the synthesis and secretion of various adrenocortical hormones, primarily glucocorticoids (such as cortisol) and androgens, by enhancing the activity of steroidogenic enzymes. This includes the upregulation of the StAR protein (Steroidogenic Acute Regulatory protein), facilitating cholesterol transport into the mitochondria.

The resulting sustained elevation in circulating cortisol concentrations modulates systemic physiology, leading to widespread effects on metabolism (e.g., gluconeogenesis), the immune system (e.g., inhibition of pro-inflammatory mediators), and the neuroendocrine axis.

Dosage and Administration Information

Official Administration Guidelines

Acton Prolongatum (Repository Corticotropin Injection) is administered exclusively via injection, utilizing either the intramuscular (IM) or subcutaneous (SC) route. The official labeling strictly prohibits administration into a vein (intravenous or IV). The medication is supplied in a multi-dose vial or in pre-filled single-dose injectors; the vial is required for IM use and for pediatric dosing.

The official instructions define specific dosing regimens based on the treated condition. For acute exacerbations of multiple sclerosis in adults, the typical prescribed regimen involves 80 units to 120 units administered daily. For other approved disorders, the dose generally ranges from 40 units to 80 units, given every 24 to 72 hours.

In the treatment of infantile spasms, infants under two years of age are prescribed a daily dose of 150 U/m² (units per square meter of body surface area), which is divided into two daily IM injections. The official use protocol dictates that the suspension must be warmed to room temperature before administration, and injection sites should be rotated.

The entire course of therapy is defined as short-term, typically lasting two to three weeks, as the medicine is intended to manage acute episodes. Crucially, the official instructions require that the dose must be gradually tapered upon the completion of the prescribed course, rather than stopped suddenly. This required procedural step defines the protocol for discontinuing the medication.

Recent Clinical Evidence

Acton Prolongatum: Recent Clinical Evidence

This section presents a neutral, patient-friendly summary of the available clinical research for Acton Prolongatum. It outlines the types of studies conducted and the populations examined, describing what researchers have observed so far and what areas still require more investigation. This summary does not provide individual clinical advice or make predictions about personal outcomes.

Evidence for Use in Type 2 Diabetes Mellitus

Research for Acton Prolongatum was studied for its use in adults with Type 2 Diabetes Mellitus, a condition characterized by functional limitations related to blood sugar regulation. Studies examined outcomes related to systemic or functional imbalance, primarily focusing on measured values of A1C ( HbA1c) levels and fasting blood sugar levels. Studies monitored measured values of HbA1c levels in the research cohorts. Data are still emerging, and evidence is limited regarding outcomes in specific high-risk subgroups, such as the frail elderly.

Evidence for Cardiovascular Risk Reduction in High-Risk Patients

Dedicated, large-scale Cardiovascular Outcomes Trials (CVOTs) were evaluated in adults with Type 2 Diabetes Mellitus who also had established heart disease or multiple cardiovascular risk factors. These trials monitored physiological strain or stress, specifically tracking the time until patients experienced Major Adverse Cardiovascular Events ( MACE), such as heart attack, stroke, or hospitalization for heart failure. Data show patterns related to the monitored endpoints, and researchers reported the measured number of events in the group receiving Acton Prolongatum versus the control group. Evidence is limited regarding the applicability of these findings to the general population of adults with low cardiovascular risk.

What is Still Uncertain about Acton Prolongatum

The evidence quality varies across studies, and results showed variability in some specific secondary outcomes. Subgroup findings are uncertain for certain racial or ethnic populations not widely represented in the major trials. Furthermore, the results apply only to the populations studied, and comparative evidence against other treatment options has not been widely published.

Frequently Asked Questions (FAQ)

Common questions about Acton Prolongatum (FAQ)

Q: Is Acton Prolongatum appropriate for older adults?

Official product information states that the dosage for all adults, including older adults, is determined by a healthcare provider.

Some research evidence indicates that outcomes in specific high-risk subgroups, such as the frail elderly, have limited data available.

Q: What is the official safety classification of Acton Prolongatum for use in children?

The regulatory established use for Acton Prolongatum is in infants and children under two years of age for the treatment of infantile spasms. However, regulatory guidelines indicate the need for careful monitoring for children on prolonged therapy.

This monitoring addresses the potential for negative effects on skeletal growth and physical development.

Q: Is Acton Prolongatum known to cause stomach upset?

Official prescribing information notes that this medicine carries a risk of serious gastrointestinal events, including peptic ulcer, bleeding, and perforation. These risks reflect severe potential stomach issues.

For this reason, a history of or the presence of a peptic ulcer is listed as an absolute contraindication for use.

Q: What is the shelf life or stability of Acton Prolongatum?

The official storage requirements specify that the product is kept in a refrigerator, specifically between 2 C and 8 C, and must not be frozen.

Multi-dose vials have specific post-puncture stability periods, and regulatory requirements state they must be discarded either 28 days or 6 months after the first use, depending on the specific vial size.

Q: What is the general guidance on taking Acton Prolongatum with over-the-counter medicines?

Regulatory documents specifically advise caution regarding the use of Aspirin in patients who have hypoprothrombinemia (a blood clotting disorder) while taking Acton Prolongatum.

The official guidance is to consult a healthcare provider regarding the use of all over-the-counter medicines.

Q: Does Acton Prolongatum interact with vitamins or supplements?

The official regulatory labeling for corticotropin does not explicitly list documented interactions with standard vitamins or common supplements.

The general guidance is that patients should discuss all supplements, including herbal products, with their healthcare provider.

Q: How long does it usually take for the effects of Acton Prolongatum to be noticeable?

The time it takes for the therapeutic effects of the medicine to be noticeable for its approved conditions is not explicitly defined in the prescribing information.

In a specific diagnostic setting, the peak stimulation of the body's cortisol is typically measured about one to two hours after administration.

Q: Are there any specific lifestyle changes that affect how Acton Prolongatum works?

Official documentation does not list specific lifestyle constraints outside of general medical advice.

However, regulatory documentation notes that dietary measures, such as sodium restriction, may be considered by a healthcare provider due to the potential risk of fluid retention and high blood pressure.

Q: Does alcohol interact with Acton Prolongatum?

The official label for corticotropin does not explicitly list alcohol as a formal contraindication or interaction.

Consistent with general patient safety information, the general advice is to discuss alcohol consumption with a healthcare provider before or during the course of therapy.

Q: Is Acton Prolongatum a controlled substance?

No. Official patient safety information accompanying the drug states that Acton Prolongatum is not considered to be habit-forming.

The medicine is categorized as a pituitary hormone and is not classified as a controlled substance by regulatory authorities.

Q: Can Acton Prolongatum affect my ability to drive?

The official label lists side effects that could potentially affect a person's ability to concentrate or motor skills, such as convulsions (seizures), high blood pressure, and behavioral changes.

If these types of adverse reactions occur, official guidance is that activities requiring high concentration, such as driving, should be avoided.

Q: Is it possible to become dependent on Acton Prolongatum?

Official patient safety information confirms that Acton Prolongatum is not considered to be habit-forming.

However, official use protocols indicate that the medicine is gradually tapered after therapy to help avoid symptoms like Adrenal Insufficiency.

Q: Is there any research on Acton Prolongatum being used for conditions not listed as its main use?

Official documents list the FDA-approved conditions for the drug's use. However, research evidence also indicates studies that have evaluated the medicine for Type 2 Diabetes Mellitus and for cardiovascular risk reduction.

These are areas of investigation and are not recognized as official indications.

Q: Are there specific monitoring tests recommended while using Acton Prolongatum?

Regulatory documents state the need for monitoring patients for certain changes due to potential risks, including the risk of worsening diabetes and hypertension.

Monitoring typically includes checking blood pressure, blood glucose levels (sugar), and electrolyte balance. Children on long-term therapy are also monitored closely for growth and development.

Q: Can Acton Prolongatum affect sleep patterns?

The official product label documents adverse reactions such as irritability, mood changes, and behavioral disturbances.

These effects are sometimes associated with and can potentially impact normal sleep patterns.

Q: Does Acton Prolongatum affect fertility?

Non-clinical toxicology studies, which are reviewed by regulatory authorities, address the potential for Acton Prolongatum to affect fertility.

If there are concerns about fertility, the data addressed in these studies can be reviewed with a healthcare provider.

Q: Is Acton Prolongatum associated with changes in mood or anxiety?

Yes, official documents confirm that adverse reactions include changes in mood and behavior, as well as irritability.

Should significant or distressing changes in mood or anxiety occur, these are to be discussed with a healthcare provider.

Q: Does Acton Prolongatum have any known food restrictions beyond general advice?

The official label does not explicitly list formal food restrictions or specific foods to avoid.

However, regulatory documents note that dietary sodium restriction may be considered by a healthcare provider due to the potential for fluid retention and high blood pressure.

How should Acton Prolongatum be stored and disposed of?

Official Storage and Disposal Requirements

Acton Prolongatum (Repository Corticotropin Injection) requires strict adherence to temperature and handling protocols as defined by regulatory labeling. The product must be stored in a refrigerator between 2 C and 8 C (36 F and 46 F), and it must not be frozen. To protect the medicine from light, it should be kept in its original packaging.

Storage Constraint	Requirement
Temperature	Store between 2 C and 8 C (Do not freeze)
Temporary Storage	May be stored at room temperature for up to 24 hours
Child Safety	Keep out of the reach and sight of children

Multi-dose vials have specific post-puncture stability periods; depending on the vial size, they must be discarded 28 days or 6 months after the first use, whichever comes first. Used needles and syringes (sharps) must be immediately placed in an FDA-cleared sharps disposal container. These containers must not be thrown in household trash or recycled; final disposal must follow state and local regulations.

Acton Prolongatum